BIOQUAL Inc. reports recurring financial results and governance updates as an OTC Pink/Pink Limited public company. Its announcements center on quarterly and annual revenue, income or loss before taxes, net income or loss, earnings per common share, and weighted average shares outstanding.
Company news also documents board and senior leadership changes, including retirements and appointments connected to corporate oversight and BIOQUAL's contract research program.
BIOQUAL (BIOQ) reported fiscal 2026 results showing lower revenue and a wider net loss compared with 2025.
Revenue for 2026 was $39,947,446, down from $48,867,753 in 2025. Loss before income tax increased to $(3,716,076) from $(1,286,601). Net loss rose to $(4,168,571), compared with $(1,048,154) the prior year. Basic and diluted loss per share were both $(4.08) in 2026, versus $(1.17) in 2025, based on a weighted average of 894,416 shares outstanding in both years.
The company also highlighted standard forward‑looking statement risks related to contracts, staffing, financing, and operational performance.
BIOQUAL (BIOQ) reported corrected fiscal 2026 financial results, with revenue falling to $39,947,446 from the prior fiscal year.
Revenue was $48,867,753 in fiscal 2025. The net loss widened to $4,168,571 from $1,048,154, while the loss before income tax increased to $3,716,076 from $1,286,601. Basic and diluted losses per common share were both $4.66, compared with $1.17 in fiscal 2025. Weighted average shares outstanding for both calculations remained at 894,416. The corrected results replace the earlier September 22, 2026 release because of an earnings-per-share error.
BIOQUAL (Pink:BIOQ) reported unaudited results for the third quarter and nine months ended February 28, 2026. Q3 revenue was $9.84M versus $14.03M year-ago; nine-month revenue was $30.68M versus $37.20M. The company reported a Q3 net loss of $752,524 and basic EPS of $(0.84).
Weighted average shares outstanding remained approximately 894,416. Management cautioned that forward-looking statements depend on contract extensions, staffing, animal model supply, and financing availability.
BIOQUAL (Pink Limited: BIOQ) reported unaudited results for the second quarter of fiscal 2026 ended November 30, 2025. Six-month revenue was $20,834,840 versus $23,165,920 a year earlier. The company reported a six-month net loss of $386,117 compared with a $1,887,527 loss in the prior year period, and a three-month net loss of $137,285 versus $1,212,202 a year earlier. Basic and diluted EPS improved to $(0.43) for six months from $(2.11) a year earlier. Weighted average shares outstanding were 894,416. Management highlighted forward-looking risks related to contracts, staffing, and financing.
BIOQUAL (Pink: BIOQ) reported unaudited results for the first quarter of fiscal 2026 ended August 31, 2025.
Key metrics: Revenue $9,855,399 versus $11,770,482 a year earlier; Loss before income tax $(343,432) versus $(931,825); Net loss $(248,832) versus $(675,325); Basic and diluted EPS $(0.28) versus $(0.76). Weighted average shares outstanding were 894,416 for basic EPS.
The company noted forward-looking risks including contract extension and funding uncertainties, workforce and animal-model availability, and capital needs.
BIOQUAL Inc. (BIOQ) reported financial results for fiscal year 2025, showing significant challenges. The company's revenue declined to $48.87 million from $58.59 million in 2024, representing a 16.6% decrease. BIOQUAL recorded a net loss of $1.05 million in 2025, compared to a net income of $483,481 in the previous year.
The company's earnings per share dropped to a loss of $1.17 per share, down from positive earnings of $0.54 in 2024. The weighted average number of shares outstanding remained stable at 894,416 shares for both basic and diluted calculations.
BIOQUAL announces a significant leadership transition as Dr. Mark G. Lewis retires from his position as President and CEO, effective May 31, 2025. Dr. Hanne Andersen Elyard, the company's current Chief Science Officer, will succeed him as President while Dr. Lewis remains Chairman of the Board.
Dr. Elyard brings impressive credentials to her new role, including a PhD in microbiology and authorship of over 105 peer-reviewed publications. Her journey at BIOQUAL spans nearly two decades, progressing from staff scientist in 2006 to Chief Scientific Officer in 2022.
Dr. Lewis, who joined BIOQUAL in 2003 as Senior Scientist and became President and CEO in 2010, expressed confidence in Dr. Elyard's leadership, citing her expertise in client contract and business operations. The transition represents a strategic move for the contract research organization as it continues to focus on growth and successful operations.
BIOQUAL (BIOQ) has announced that Board Member Michael P. O'Flaherty will retire effective May 1, 2025. O'Flaherty, who is 86 years old, previously served as the company's Chief Operating Officer and Secretary until his retirement in 2015, after which he was elected to the Board. The company clarified that his departure is not related to any disagreements with Board policies or practices.
The announcement includes forward-looking statements addressing various business risks, including the company's ability to extend government contracts, obtain new contracts, maintain animal model demand for scientific research, secure adequate staffing, and manage operational costs. The statement also highlights potential challenges regarding capital needs and future financing.
BIOQUAL (OTC Pink: BIOQ) has released its unaudited financial results for the third quarter of fiscal year 2025. The company reported quarterly revenue of $14.03 million, down from $15.34 million in the same period last year.
For the nine months ended February 28, 2025, revenue decreased to $37.20 million from $46.79 million year-over-year. The company posted a quarterly net income of $936,030 ($1.05 per share), compared to $275,026 ($0.31 per share) in Q3 2024. However, for the nine-month period, BIOQUAL recorded a net loss of $951,497 (-$1.06 per share) versus a net income of $1.66 million ($1.86 per share) in the previous year.
BIOQUAL (BIOQ) has reported its unaudited financial results for the second quarter of fiscal year 2025, showing significant declines across key metrics. Revenue decreased to $23.17 million for the six months ended November 30, 2024, down from $31.45 million in the same period of 2023. The company reported a net loss of $1.89 million for the six-month period, compared to a net income of $1.38 million in the previous year.
For the three-month period ended November 30, 2024, revenue was $11.40 million, down from $15.87 million, with a net loss of $1.21 million compared to a net income of $484,661 in the prior year. Basic and diluted earnings per share declined to ($2.11) for the six-month period, compared to $1.55 in 2023.